Ovid therapeutics Inc (OVID)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$2.70-1.82%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Ovid is developing new medicines for neurological disorders. It recently showed positive data for OV329 and cleared Phase 1 for OV4071. The company has a new CEO and director to improve execution. These steps could lead to future growth and value creation.
Ovid is still loss-making with negative EPS expected through 2027. Analysts forecast a 92% revenue decline next year. The company relies on capital raises, which dilute shareholders. Execution risks and lack of clear revenue guidance remain high.
The stock trades about 45% above our fair value near $1.88. Analysts expect revenue to fall about 92% next year, reflecting very weak near-term outlook. Our view is more cautious on recovery timing and value.
Breaks if: announces dilutive capital raise within next 12 months
Breaks if: EPS loss does not improve or worsens in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making, and while it has some promising clinical developments, its recent financial performance has been weak.
The current valuation reflects a premium compared to peers, suggesting that the market has high expectations for future performance. However, this premium may not be justified given the company's recent struggles and the elevated risks it faces.
Management is making progress on key clinical developments, particularly with OV4071 and OV329, which are on track. However, the overall financial performance remains weak, and the company operates in a high-miss-rate industry, which adds to the uncertainty.
The long-term thesis hinges on the company's ability to maintain its financial runway and successfully advance its clinical programs. Additionally, external factors such as sector performance and economic conditions will significantly impact OVID's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no current threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: failure to meet clinical or regulatory milestones in next 12 months
Breaks if: revenue growth falls below 0% in FY27
In the next 1 to 3 years, OVID's success will depend on its clinical advancements and broader market conditions. Not investment advice.